GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-11-03| IPO

Alkermes to Break Oncology Sector into Independent Company

by Reed Slater
Share To

After some early success with its new schizophrenia treatment and high hopes for its future, Alkermes announced its intent to separate its neuroscience and oncology divisions, moving its cancer treatment development programs to an independent company. The tentatively named Oncology Co. would be publicly traded and financially independent from Alkermes, which would remain focused on neuroscience products and development.

Banking on Lybalvi’s Success

The driving force behind the split between Alkermes’ neuroscience and oncology divisions is the company’s expectations for its new schizophrenia treatment, Lybalvi. Approved last October, the drug is already generating substantial revenue for Alkermes. The company posted third-quarter results earlier this week, with Lybalvi bringing in $27.1 million.

Alkermes’ other commercialized neuroscience products include Aristada, another schizophrenia treatment, and Vivitrol, a substance abuse treatment. In total, the company’s proprietary products brought in $199.4 million by the end of the third quarter. 

Based on the neuroscience division’s current success, Alkermes plans to separate the oncology sector to simplify strategies and fund allocations. The company says the separation would benefit shareholders and allow both areas to thrive with the care and attention they need.

Lead Independent Director of Alkermes’ Board, Nancy Wysenski, said, “The potential separation of the oncology business from Alkermes’ neuroscience business would offer a platform to enhance the performance of both businesses and unlock shareholder value…as we look ahead, the Board unanimously agrees that the unique needs of each business would be best served by simplified resource and capital allocation decision making, tailored operating structures, and distinct leadership teams, each with a clearly defined strategic focus.”

Related Article: Nineteen Grants and Two Contracts Grab $38 Million In Support From the FDA

Forming an Independent Oncology Company

With several development candidates in Alkermes’ pipeline, the future Oncology Co. is on track for a successful industry debut. Alkermes said it hopes to finalize the separation and launch of Oncology Co. in the second half of next year. 

One of Alkermes’ primary oncology focuses lies in its IL-2 variant immunotherapy, nemvaleukin. The investigational drug is in Phase 2 and 3 studies evaluating its effect on mucosal melanoma and platinum-resistant ovarian cancer. 

The new company would also continue developing preclinical prospects targeting IL-12 and IL-18. Alkermes is also developing HDAC inhibitors, which are in the preclinical phases.

Alkermes plans on locating the future Oncology Co. at the current Waltham, Massachusetts campus. The manufacturing and research facilities in Wilmington, Ohio, and Athlone, Ireland, will remain in Alkermes’ hands. The separation is subject to customary closing conditions and the Board of Directors’ final approval. 

Separating Alkermes’ neuroscience and oncology divisions would provide independent fund allocations for each while allowing specialized teams to develop targeted strategies for each company. If the deal closes and Oncology Co. launches, it would likely happen in the second half of next year. Until then, Alkermes will continue developing and selling novel therapies while it continues to plan for the massive restructuring. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
IPO
China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M
2025-01-24
Biotech and Pharma IPOs Surge with Innovative Therapies in the Beginning of 2024: From Kymera Therapeutics to Kyverna Therapeutics Lead the Way
2024-01-18
IPO
Exploring AI’s Impact on Biotech Breakthroughs and International Funding
2023-08-29
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top